iadademstat
Small moleculeexperimental
Clinical trial activity
9 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2016 (NCT02913443)
Timeline
Indications
Studied for
- Carcinoma, Neuroendocrine · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 2
- Polycythemia Vera · Phase 2
- Primary Myelofibrosis · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Thrombocythemia, Essential · Phase 2
Mechanism of action
KDM1A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N[C@H]1CC[C@H](N[C@@H]2C[C@H]2c2ccccc2)CC1- Mol. weight
- 230.35 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3781751 ↗
Also known as
- ro7051790
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07113691 | Phase 1 | Nov 30, 2025 | Genentech, Oryzon Genomics S.A., Yale University |
| NCT06514261 | Phase 1 | Jul 15, 2025 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT06661915 | Phase 2 | Jan 31, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06502145 | Phase 1 | Oct 31, 2024 | Medical College of Wisconsin |
| NCT06287775 | Phase 1/Phase 2 (Phase 2) | Oct 18, 2024 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT06357182 | Phase 1 | Sep 16, 2024 | OHSU Knight Cancer Institute, Oregon Health and Science University, Oryzon Genomics S.A. |
| NCT05420636 | Phase 2 | Dec 31, 2022 | Oryzon Genomics S.A., Temple University |
| NCT05546580 | Phase 1 | Oct 15, 2022 | Oryzon Genomics S.A. |
| NCT02913443 | Phase 1 | Nov 30, 2016 | Roche |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oryzon Genomics S.A. | For profit | 4 | 1 | 2 | 2022 |
| National Cancer Institute (NCI) | Government | 3 | 3 | 2 | 2024 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Genentech | For profit | 1 | 0 | 1 | 2025 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 1 | 1 | 2024 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Roche | For profit | 1 | 1 | 1 | 2016 |
| Temple University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2025 |
12 organizations
Page 1 / 1